Form 4: Quest Diagnostics Director Reports Future Stock Acquisition via DRIP Under 10b5-1 Plan

Quest Diagnostics director Wright L. Lassiter III reported the future acquisition of 7 shares of common stock through a dividend reinvestment plan under a Rule 10b5-1 trading plan.

Summary

• Wright L. Lassiter III, a Director of Quest Diagnostics Inc. (DGX), is the reporting person.
• The filing reports the acquisition of 7 shares of DGX Common Stock.
• The transaction date is specified as July 21, 2025, indicating a future, pre-scheduled acquisition.
• The acquisition price per share is $167.505.
• Following this transaction, the director will beneficially own 9,044 shares of common stock directly.
• The shares are being acquired pursuant to a dividend reinvestment plan (DRIP).
• The transaction was made pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
• The reporting person chose to report this transaction early on Form 4, although it was eligible for deferred reporting on Form 5 under Rule 16a-6.

Sentiment

Score: 6

Explanation: The filing indicates a minor, pre-planned acquisition of shares by a director through a dividend reinvestment plan, which is a slightly positive signal of continued insider confidence, but not a significant event.

Positives

• The acquisition, even if small, indicates continued participation and confidence by a director in the company's equity.
• The transaction is part of a dividend reinvestment plan, suggesting a long-term investment strategy.
• The transaction being conducted under a Rule 10b5-1 plan demonstrates a pre-planned, non-discretionary approach to stock acquisition, which can mitigate concerns about opportunistic insider trading.

Future Outlook

The filing indicates a pre-scheduled future acquisition of shares by a director, reflecting ongoing participation in the company's equity through a dividend reinvestment plan under a 10b5-1 trading plan.

Industry Context

This Form 4 filing is a routine disclosure of an insider's planned stock transaction and does not provide broader industry context or trends. It is specific to the individual's investment activity within Quest Diagnostics.

Stakeholder Impact

• Shareholders: Provides a minor positive signal of continued insider confidence in the company's stock, as a director is increasing their stake, albeit through a routine DRIP.

Key Dates

Recommendation

The filing details a routine, small acquisition of shares by a director through a dividend reinvestment plan under a 10b5-1 plan. This type of transaction is generally expected and does not provide sufficient new information to warrant a change in a fundamental investment thesis or a strong buy/sell recommendation. It primarily signals continued, albeit minor, insider confidence.

Keywords

Quest Diagnostics, DGX, Form 4, Insider Transaction, Director, Stock Acquisition, Dividend Reinvestment Plan, 10b5-1 Plan, Common Stock